Ignite Creation Date:
2024-05-06 @ 3:25 PM
Last Modification Date:
2024-10-26 @ 1:49 PM
Study NCT ID:
NCT04624113
Status:
TERMINATED
Last Update Posted:
2024-02-21
First Post:
2020-11-09
Brief Title:
Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
Sponsor:
Washington University School of Medicine
Organization:
Washington University School of Medicine
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-04-14
Start Date Type:
ACTUAL
Primary Completion Date:
2022-08-09
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-02-17
Completion Date Type:
ACTUAL
First Submit Date:
2020-11-09
First Submit QC Date:
November 9 2020
Study First Post Date:
2020-11-10
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-02-19
Last Update Post Date:
2024-02-21
Last Update Post Date Type:
ACTUAL